Condition: Diabetes Mellitus · Cardiovascular Diseases · Sponsor: National Heart Centre Singapore
The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (\>125pg/mL), and (2) intensify therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this high-risk DM population.
This description comes directly from the study's public registry record.
Serene Ng Miss · 67042232 · serene.ng.b.l@singhealth.com.sg
Salma Asali Miss · 67042303 · asali.salma@singhealth.com.sg
Always discuss trial participation with your own doctor first.
| Singapore General Hospital (SGH) | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04286399